Noninvasive determinants of pulmonary hypertension in interstitial lung disease

被引:12
|
作者
Joseph, Phillip [1 ,5 ]
Savarimuthu, Stella [1 ]
Zhao, Jiayi [2 ]
Yan, Xiting [1 ]
Oakland, Hannah T. [1 ]
Cullinan, Marjorie [3 ]
Heerdt, Paul M. [4 ]
Singh, Inderjit [1 ]
机构
[1] Yale New Haven Hosp, Yale Sch Med, Dept Med, Div Pulm, New Haven, CT 06520 USA
[2] Yale Sch Publ Hlth, Dept Biostat, New Haven, CT USA
[3] Yale New Haven Hosp, Dept Resp Care, New Haven, CT USA
[4] Yale New Haven Hosp, Yale Sch Med, Dept Anaesthesiol, New Haven, CT USA
[5] Yale New Haven Hosp, Yale Sch Med, Dept Med, Div Pulm, New Haven, CT 06511 USA
关键词
cardiopulmonary exercise testing; interstitial lung disease; pulmonary hypertension; NATRIURETIC PEPTIDE LEVELS; INHALED TREPROSTINIL; EXERCISE; VENTILATION; PRESSURE; OBESITY; IMPACT;
D O I
10.1002/pul2.12197
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pulmonary hypertension (PH) in interstitial lung disease (ILD) is associated with increased mortality and impaired exertional capacity. Right heart catheterization is the diagnostic standard for PH but is invasive and not readily available. Noninvasive physiologic evaluation may predict PH in ILD. Forty-four patients with PH and ILD (PH-ILD) were compared with 22 with ILD alone (non-PH ILD). Six-min walk distance (6MWD, 223 +/- 131 vs. 331 +/- 125 m, p = 0.02) and diffusing capacity for carbon monoxide (DLCO, 33 +/- 14% vs. 55 +/- 21%, p < 0.001) were lower in patients with PH-ILD. PH-ILD patients exhibited a lower gas-exchange derived pulmonary vascular capacitance (GX(CAP), 251 +/- 132 vs. 465 +/- 282 mL x mmHg, p < 0.0001) and extrapolated maximum oxygen uptake (VO2max) (56 +/- 32% vs. 84 +/- 37%, p = 0.003). Multivariate analysis was performed to determine predictors of VO2max. GX(CAP) was the only variable that predicted extrapolated VO2max among PH-ILD and non-PH ILD patients. Receiver operating characteristic curve analysis assessed the ability of individual noninvasive variables to distinguish between PH-ILD and non-PH ILD patients. GX(CAP) (area under the curve [AUC] 0.85 +/- 0.04, p < 0.0001) and delta ETCO2 (AUC 0.84 +/- 0.04, p < 0.0001) were the strongest predictors of PH-ILD. A CART analysis selected GX(CAP), estimated right ventricular systolic pressure (eRVSP) by echocardiogram, and FVC/DLCO ratio as predictive variables for PH-ILD. With this analysis, the AUC improved to 0.94 (sensitivity of 0.86 and sensitivity of 0.93). Patients with a GX(CAP) <= 416 mL x mmHg had an 82% probability of PH-ILD. Patients with GX(CAP) <= 416 mL x mmHg and high FVC/DLCO ratio >1.7 had an 80% probability of PH-ILD. Patients with GX(CAP) <= 416 mL x mmHg and an elevated eRVSP by echocardiogram >43 mmHg had 100% probability of PH-ILD. The incorporation of GX(CAP) with either eRVSP or FVC/DLCO ratio distinguishes between PH-ILD and non-PH-ILD with high probability and may therefore assist in determining the need to proceed with a diagnostic right heart catheterization and potential initiation of pulmonary arterial hypertension-directed therapy in PH-ILD patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Response to letter to the editor "noninvasive determinants of pulmonary hypertension in interstitial lung disease"
    Joseph, Phillip
    Savarimuthu, Stella
    Oakland, Hannah T. T.
    Cullinan, Marjorie
    Heerdt, Paul M. M.
    Singh, Inderjit
    PULMONARY CIRCULATION, 2023, 13 (02)
  • [2] Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
    Haynes, Zachary A.
    Chandel, Abhimanyu
    King, Christopher S.
    CELLS, 2023, 12 (19)
  • [3] Pulmonary hypertension due to interstitial lung disease
    King, Christopher S.
    Nathan, Steven D.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (05) : 459 - 467
  • [4] Pulmonary hypertension in interstitial lung disease
    Behr, J.
    Ryu, J. H.
    EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (06) : 1357 - 1367
  • [5] Efficacy and determinants of response to inhaled treprostinil in pulmonary hypertension - interstitial lung disease
    Balakrishnan, Bathmapriya
    Azar, Jehad
    Farha, Samar
    Goyanes, Alice M.
    Lane, James E.
    Paul, Deborah
    Highland, Kristin B.
    Wang, Yifan
    Wang, Xiaofeng
    Tonelli, Adriano R.
    RESPIRATORY MEDICINE, 2024, 234
  • [6] Pulmonary hypertension in patients with interstitial lung disease
    Karampitsakos, Theodoros
    Tzouvelekis, Argyrios
    Chrysikos, Serafeim
    Bouros, Demosthenes
    Tsangaris, Iraklis
    Fares, Wassim H.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 50 : 38 - 46
  • [7] Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
    Lawrence, Alexandra
    Myall, Katherine Jane
    Mukherjee, Bhashkar
    Marino, Philip
    LIFE-BASEL, 2024, 14 (09):
  • [8] Pulmonary Hypertension in Interstitial Lung Disease
    Baldi, Bruno Guedes
    Souza, Rogerio
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (10): : 685 - 686
  • [9] Pulmonary hypertension in interstitial lung disease
    Polomis, David
    Runo, James R.
    Meyer, Keith C.
    CURRENT OPINION IN PULMONARY MEDICINE, 2008, 14 (05) : 462 - 469
  • [10] The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease
    Corte, Tamera J.
    Gatzoulis, Michael A.
    Parfitt, Lisa
    Harries, Carl
    Wells, Athol U.
    Wort, S. John
    RESPIROLOGY, 2010, 15 (08) : 1226 - 1232